The IPO market closed out June with four deals, three of which raised $100+ million. In the pipeline, nine companies submitted initial filings, led by what could be the largest IPO of 2024 to date. Web comic platform WEBTOON Entertainment...read more
Alumis, a Phase 3-ready biotech developing kinase inhibitors for immune-mediated diseases, raised $210 million by offering 13.1 million shares at $16, the low end of the range of $16 to $18. The company offered 4.5 million fewer shares than anticipated. Alumis...read more
Alumis, a Phase 3-ready biotech developing kinase inhibitors for immune-mediated diseases, announced terms for its IPO on Monday. The South San Francisco, CA-based company plans to raise $300 million by offering 17.7 million shares at a price range of $16 to...read more
Updated Monday, 6/24. Four IPOs are currently scheduled to debut in the week ahead as the second quarter comes to a close. Immunology biotech Alumis (ALMS) plans to raise $300 million at a $1.0 billion market cap. The company is...read more
US IPO Weekly Recap: 2Q IPO market closes out with sizable pricings and pipeline additions
The IPO market closed out June with four deals, three of which raised $100+ million. In the pipeline, nine companies submitted initial filings, led by what could be the largest IPO of 2024 to date. Web comic platform WEBTOON Entertainment...read more
Immunology biotech Alumis prices downsized IPO at $16, the low end of the range
Alumis, a Phase 3-ready biotech developing kinase inhibitors for immune-mediated diseases, raised $210 million by offering 13.1 million shares at $16, the low end of the range of $16 to $18. The company offered 4.5 million fewer shares than anticipated. Alumis...read more
Immunology biotech Alumis sets terms for $300 million IPO
Alumis, a Phase 3-ready biotech developing kinase inhibitors for immune-mediated diseases, announced terms for its IPO on Monday. The South San Francisco, CA-based company plans to raise $300 million by offering 17.7 million shares at a price range of $16 to...read more
US IPO Week Ahead: Carve-outs, cross-listings, and energy plays close out the 2Q IPO market
Updated Monday, 6/24. Four IPOs are currently scheduled to debut in the week ahead as the second quarter comes to a close. Immunology biotech Alumis (ALMS) plans to raise $300 million at a $1.0 billion market cap. The company is...read more